Najat Khan - Aug 15, 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Signature
/s/ Kyle Nelson, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Aug 15, 2025
Transactions value $
-$223,543
Form type
4
Date filed
8/19/2025, 06:22 PM
Previous filing
May 19, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khan Najat Chief R&D Commercial Officer, Director 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 2025-08-19 0002020969

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Tax liability -$21.4K -3.79K -0.53% $5.64 705K Aug 15, 2025 Direct F1
transaction RXRX Class A Common Stock Sale -$202K -36.6K -5.19% $5.52 668K Aug 18, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2 Represents shares that have been required to be sold by the Issuer to satisfy the tax withholding and remittance obligations in connection with the vesting of restricted stock units.